SERA vs OVID

For growth investors, Ovid Therapeutics Inc.

(OVID) is the stronger pick with 1181% revenue growth year-over-year, versus 5. 2% for Sera Prognostics, Inc. (SERA). Analysts rate Sera Prognostics, Inc. (SERA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ovid Therapeutics Inc.

(OVID) delivered a total return of -21. 6%, compared to -83. 9% for Sera Prognostics, Inc. (SERA). Over 10 years, the gap is even starker: OVID returned -77. 7% versus SERA's -83. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ovid Therapeutics Inc.

(OVID) is the lower-risk stock at 1. 45β versus Sera Prognostics, Inc. 's 1. 56β — meaning SERA is approximately 7% more volatile than OVID relative to the S&P 500. On balance sheet safety, Ovid Therapeutics Inc. (OVID) carries a lower debt/equity ratio of 1% versus 3% for Sera Prognostics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ovid Therapeutics Inc.

(OVID) is pulling ahead at 1181% versus 5. 2% for Sera Prognostics, Inc. (SERA). On earnings-per-share growth, the picture is similar: Ovid Therapeutics Inc. grew EPS 35. 1% year-over-year, compared to 32. 3% for Sera Prognostics, Inc.. Over a 3-year CAGR, OVID leads at 69. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ovid Therapeutics Inc.

(OVID) is the more profitable company, earning -240. 1% net margin versus -394. 2% for Sera Prognostics, Inc. — meaning it keeps -240. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OVID leads at -585. 2% versus -450. 7% for SERA. At the gross margin level — before operating expenses — OVID leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ovid Therapeutics Inc.

(OVID) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Sera Prognostics, Inc. (SERA) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OVID: -77. 7%, SERA: -83. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SERA is a small-cap quality compounder stock; OVID is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.